Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomySodium phosphate
Identification
- Name
- Sodium phosphate
- Accession Number
- DB09449 (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525)
- Type
- Small Molecule
- Groups
- Approved
- Description
Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
- Structure
Structure for DB09449 (Sodium phosphate)
- Synonyms
- Sodium orthophosphate
- Sodium phosphate monobasic
- Sodium phosphate monobasic (anhydrate)
- Sodium phosphate, unspecified
- Sodium phosphates
- Product Ingredients
Ingredient UNII CAS InChI Key Sodium phosphate, dibasic BWZ7K44R51 10140-65-5 LVXHNCUCBXIIPE-UHFFFAOYSA-L Sodium phosphate, dibasic dihydrate 94255I6E2T 10028-24-7 KDQPSPMLNJTZAL-UHFFFAOYSA-L Sodium phosphate, dibasic dodecahydrate E1W4N241FO 10039-32-4 DGLRDKLJZLEJCY-UHFFFAOYSA-L Sodium phosphate, dibasic, anhydrous 22ADO53M6F 7558-79-4 BNIILDVGGAEEIG-UHFFFAOYSA-L Sodium phosphate, dibasic, heptahydrate 70WT22SF4B 7782-85-6 PYLIXCKOHOHGKQ-UHFFFAOYSA-L Sodium phosphate, monobasic, anhydrous Not Available 7558-80-7 AJPJDKMHJJGVTQ-UHFFFAOYSA-M Sodium phosphate, monobasic, dihydrate 5QWK665956 13472-35-0 VBJGJHBYWREJQD-UHFFFAOYSA-M Sodium phosphate, monobasic, monohydrate 593YOG76RN 10049-21-5 BBMHARZCALWXSL-UHFFFAOYSA-M Sodium phosphate, monobasic, unspecified form 3980JIH2SW Not Available Not applicable - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End IMUFLEX WB-RP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Removing Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative Kit Intravenous Terumo Corporation 2010-02-26 Not applicable US 
IMUFLEX WB-SP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative Kit Intravenous Terumo Corporation 2010-12-15 Not applicable US Leucoflex CGP Kit Maco Productions 2013-05-31 Not applicable US MTL1 Leucoflex Kit Intravenous Maco Productions 2005-11-21 Not applicable US TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL Red Cell Preservative Kit Intravenous Terumo Corporation 2009-12-15 Not applicable US TERUFLEX Blood Bag System with Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative Kit Intravenous Terumo Corporation 2010-05-05 Not applicable US TERUFLEX Blood Bag System with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative Kit Intravenous Terumo Corporation 2010-05-05 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Additive Solution Formula 3 As-3 Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Glucose (1.10 g) + Sodium Chloride (0.410 g) + Sodium citrate dihydrate (0.588 g) Solution Unknown Terumo Bct, Inc. 2013-05-31 Not applicable Canada 
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2009-05-15 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2007-06-06 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2007-06-11 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + Dextrose monohydrate (1.61 g/63mL) + Dextrose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) Kit Fenwal, Inc. 2010-09-28 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + Dextrose monohydrate (1.61 g/63mL) + Dextrose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic) Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) Kit Fenwal, Inc. 2007-03-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Azuphen Mb Sodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (120 mg/1) + Methylene blue (10 mg/1) + Phenyl salicylate (36 mg/1) Capsule Oral Burel Pharmaceuticals, Llc 2015-09-28 2018-01-06 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Cardinal Health 2012-06-28 2018-05-23 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Avera Mc Kennan Hospital 2015-03-11 2018-06-07 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Amerincan Health Packaging 2014-06-02 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Rising Pharmaceuticals 2012-06-28 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Carilion Materials Management 2012-06-28 Not applicable US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Kaiser Foundations Hospitals 2014-07-07 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Amerincan Health Packaging 2014-06-02 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Cardinal Health 2012-06-28 2018-05-23 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) Tablet Oral Avera Mc Kennan Hospital 2015-03-11 2018-06-07 US - Categories
- Acids
- Acids, Noncarboxylic
- Alimentary Tract and Metabolism
- Anions
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Drugs for Constipation
- Electrolyte Solutions
- Electrolytes
- Enemas
- I.V. Solution Additives
- Ions
- Osmotically Acting Laxatives
- Phosphate salts
- Phosphoric Acids
- Phosphorus Acids
- Phosphorus Compounds
- UNII
- KH7I04HPUU
- CAS number
- 7632-05-5
- Weight
- Average: 119.977
Monoisotopic: 119.958839739 - Chemical Formula
- H2NaO4P
- InChI Key
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M
- InChI
- InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
- IUPAC Name
- sodium dihydrogen phosphate
- SMILES
- [Na+].OP(O)([O-])=O
Pharmacology
- Indication
Used to treat constipation or to clean the bowel before a colonoscopy [FDA Label].
- Associated Conditions
- Associated Therapies
- Pharmacodynamics
Sodium phosphate inceases fecal water content to increase mobility through the large intestine [1].
- Mechanism of action
Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen [1].
- Absorption
Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h [3].
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats [7]. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma [4]. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients [3].
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene Sodium phosphate may increase the nephrotoxic activities of (4R)-limonene. Investigational Aceclofenac Sodium phosphate may increase the nephrotoxic activities of Aceclofenac. Approved, Investigational Acemetacin Sodium phosphate may increase the nephrotoxic activities of Acemetacin. Approved, Experimental, Investigational Acetazolamide Acetazolamide may increase the nephrotoxic activities of Sodium phosphate. Approved, Vet Approved Acetylsalicylic acid Sodium phosphate may increase the nephrotoxic activities of Acetylsalicylic acid. Approved, Vet Approved Adapalene Sodium phosphate may increase the nephrotoxic activities of Adapalene. Approved Alclofenac Sodium phosphate may increase the nephrotoxic activities of Alclofenac. Approved, Withdrawn Almasilate Almasilate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Alminoprofen Sodium phosphate may increase the nephrotoxic activities of Alminoprofen. Experimental Aloglutamol Aloglutamol can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Aluminium Aluminium can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Amiloride Amiloride may increase the nephrotoxic activities of Sodium phosphate. Approved Amineptine The risk or severity of adverse effects can be increased when Amineptine is combined with Sodium phosphate. Illicit, Withdrawn Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Sodium phosphate. Approved Amitriptylinoxide The risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Sodium phosphate. Approved, Investigational Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Sodium phosphate. Approved Andrographolide Sodium phosphate may increase the nephrotoxic activities of Andrographolide. Investigational Anisodamine Sodium phosphate may increase the nephrotoxic activities of Anisodamine. Investigational Antipyrine Sodium phosphate may increase the nephrotoxic activities of Antipyrine. Approved, Investigational Apocynin Sodium phosphate may increase the nephrotoxic activities of Apocynin. Investigational Apremilast Sodium phosphate may increase the nephrotoxic activities of Apremilast. Approved, Investigational Azapropazone Sodium phosphate may increase the nephrotoxic activities of Azapropazone. Withdrawn Azelastine Sodium phosphate may increase the nephrotoxic activities of Azelastine. Approved Azilsartan medoxomil Azilsartan medoxomil may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Azosemide Azosemide may increase the nephrotoxic activities of Sodium phosphate. Investigational Balsalazide Sodium phosphate may increase the nephrotoxic activities of Balsalazide. Approved, Investigational Benazepril Benazepril may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Bendazac Sodium phosphate may increase the nephrotoxic activities of Bendazac. Experimental Bendroflumethiazide Bendroflumethiazide may increase the nephrotoxic activities of Sodium phosphate. Approved Benorilate Sodium phosphate may increase the nephrotoxic activities of Benorilate. Experimental Benoxaprofen Sodium phosphate may increase the nephrotoxic activities of Benoxaprofen. Withdrawn Benzydamine Sodium phosphate may increase the nephrotoxic activities of Benzydamine. Approved Bevonium Sodium phosphate may increase the nephrotoxic activities of Bevonium. Experimental Bismuth Subcitrate Bismuth Subcitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bromfenac Sodium phosphate may increase the nephrotoxic activities of Bromfenac. Approved Bromotheophylline Bromotheophylline may increase the nephrotoxic activities of Sodium phosphate. Approved Bucillamine Sodium phosphate may increase the nephrotoxic activities of Bucillamine. Investigational Bufexamac Sodium phosphate may increase the nephrotoxic activities of Bufexamac. Approved, Experimental Bumadizone Sodium phosphate may increase the nephrotoxic activities of Bumadizone. Experimental Bumetanide Bumetanide may increase the nephrotoxic activities of Sodium phosphate. Approved Butriptyline The risk or severity of adverse effects can be increased when Butriptyline is combined with Sodium phosphate. Approved Calcium Acetate Calcium Acetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Chloride Calcium Chloride can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Citrate Calcium Citrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium glubionate Calcium glubionate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Gluceptate Calcium Gluceptate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Calcium lactate Calcium lactate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Calcium lactate gluconate Calcium lactate gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium levulinate Calcium levulinate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Calcium pangamate Calcium pangamate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium silicate Calcium silicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Candesartan Candesartan may increase the nephrotoxic activities of Sodium phosphate. Experimental Candesartan cilexetil Candesartan cilexetil may increase the nephrotoxic activities of Sodium phosphate. Approved Candoxatril Candoxatril may increase the nephrotoxic activities of Sodium phosphate. Experimental Canrenoic acid Canrenoic acid may increase the nephrotoxic activities of Sodium phosphate. Approved, Withdrawn Canrenone Canrenone may increase the nephrotoxic activities of Sodium phosphate. Investigational Captopril Captopril may increase the nephrotoxic activities of Sodium phosphate. Approved Carbaspirin calcium Sodium phosphate may increase the nephrotoxic activities of Carbaspirin calcium. Experimental, Investigational Carprofen Sodium phosphate may increase the nephrotoxic activities of Carprofen. Approved, Vet Approved, Withdrawn Casein Casein can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Castanospermine Sodium phosphate may increase the nephrotoxic activities of Castanospermine. Experimental Celecoxib Sodium phosphate may increase the nephrotoxic activities of Celecoxib. Approved, Investigational Chloroquine Sodium phosphate may increase the nephrotoxic activities of Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide Chlorothiazide may increase the nephrotoxic activities of Sodium phosphate. Approved, Vet Approved Chlorthalidone Chlorthalidone may increase the nephrotoxic activities of Sodium phosphate. Approved Choline magnesium trisalicylate Sodium phosphate may increase the nephrotoxic activities of Choline magnesium trisalicylate. Approved Cicletanine Cicletanine may increase the nephrotoxic activities of Sodium phosphate. Investigational Cilazapril Cilazapril may increase the nephrotoxic activities of Sodium phosphate. Approved Clofenamide Clofenamide may increase the nephrotoxic activities of Sodium phosphate. Experimental Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Sodium phosphate. Approved, Investigational, Vet Approved Clonixin Sodium phosphate may increase the nephrotoxic activities of Clonixin. Approved Clopamide Clopamide may increase the nephrotoxic activities of Sodium phosphate. Experimental Clorexolone Clorexolone may increase the nephrotoxic activities of Sodium phosphate. Experimental Conivaptan Conivaptan may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Curcumin Sodium phosphate may increase the nephrotoxic activities of Curcumin. Approved, Investigational Cyclopenthiazide Cyclopenthiazide may increase the nephrotoxic activities of Sodium phosphate. Experimental Cyclothiazide Cyclothiazide may increase the nephrotoxic activities of Sodium phosphate. Approved Delapril Delapril may increase the nephrotoxic activities of Sodium phosphate. Experimental Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate. Approved, Investigational Dibenzepin The risk or severity of adverse effects can be increased when Dibenzepin is combined with Sodium phosphate. Experimental Diclofenac Sodium phosphate may increase the nephrotoxic activities of Diclofenac. Approved, Vet Approved Difenpiramide Sodium phosphate may increase the nephrotoxic activities of Difenpiramide. Experimental Diflunisal Sodium phosphate may increase the nephrotoxic activities of Diflunisal. Approved, Investigational Dimetacrine The risk or severity of adverse effects can be increased when Dimetacrine is combined with Sodium phosphate. Approved, Withdrawn Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Sodium phosphate. Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate. Approved, Investigational Drospirenone Drospirenone may increase the nephrotoxic activities of Sodium phosphate. Approved Droxicam Sodium phosphate may increase the nephrotoxic activities of Droxicam. Withdrawn Duvelisib Sodium phosphate may increase the nephrotoxic activities of Duvelisib. Investigational E-6201 Sodium phosphate may increase the nephrotoxic activities of E-6201. Investigational Efonidipine Efonidipine may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Enalapril Enalapril may increase the nephrotoxic activities of Sodium phosphate. Approved, Vet Approved Enalaprilat Enalaprilat may increase the nephrotoxic activities of Sodium phosphate. Approved Epirizole Sodium phosphate may increase the nephrotoxic activities of Epirizole. Approved Epitizide Epitizide may increase the nephrotoxic activities of Sodium phosphate. Experimental Eplerenone Eplerenone may increase the nephrotoxic activities of Sodium phosphate. Approved Eprosartan Eprosartan may increase the nephrotoxic activities of Sodium phosphate. Approved Etacrynic acid Etacrynic acid may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Etanercept Sodium phosphate may increase the nephrotoxic activities of Etanercept. Approved, Investigational Ethenzamide Sodium phosphate may increase the nephrotoxic activities of Ethenzamide. Experimental Ethoxzolamide Ethoxzolamide may increase the nephrotoxic activities of Sodium phosphate. Withdrawn Etodolac Sodium phosphate may increase the nephrotoxic activities of Etodolac. Approved, Investigational, Vet Approved Etofenamate Sodium phosphate may increase the nephrotoxic activities of Etofenamate. Approved, Investigational Etoricoxib Sodium phosphate may increase the nephrotoxic activities of Etoricoxib. Approved, Investigational Evening primrose oil Sodium phosphate may increase the nephrotoxic activities of Evening primrose oil. Investigational, Nutraceutical Exisulind Sodium phosphate may increase the nephrotoxic activities of Exisulind. Investigational Felbinac Sodium phosphate may increase the nephrotoxic activities of Felbinac. Experimental Fenbufen Sodium phosphate may increase the nephrotoxic activities of Fenbufen. Approved Fenoprofen Sodium phosphate may increase the nephrotoxic activities of Fenoprofen. Approved Fenquizone Fenquizone may increase the nephrotoxic activities of Sodium phosphate. Experimental Fentiazac Sodium phosphate may increase the nephrotoxic activities of Fentiazac. Experimental Feprazone Sodium phosphate may increase the nephrotoxic activities of Feprazone. Experimental Ferric Carboxymaltose Ferric Carboxymaltose can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ferric pyrophosphate Ferric pyrophosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Ferulic acid Sodium phosphate may increase the nephrotoxic activities of Ferulic acid. Experimental Fimasartan Fimasartan may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Floctafenine Sodium phosphate may increase the nephrotoxic activities of Floctafenine. Approved, Withdrawn Flunixin Sodium phosphate may increase the nephrotoxic activities of Flunixin. Vet Approved Flunoxaprofen Sodium phosphate may increase the nephrotoxic activities of Flunoxaprofen. Experimental Flurbiprofen Sodium phosphate may increase the nephrotoxic activities of Flurbiprofen. Approved, Investigational Forasartan Forasartan may increase the nephrotoxic activities of Sodium phosphate. Experimental Fosinopril Fosinopril may increase the nephrotoxic activities of Sodium phosphate. Approved Furosemide Furosemide may increase the nephrotoxic activities of Sodium phosphate. Approved, Vet Approved Guacetisal Sodium phosphate may increase the nephrotoxic activities of Guacetisal. Experimental Higenamine Sodium phosphate may increase the nephrotoxic activities of Higenamine. Investigational Hydrochlorothiazide Hydrochlorothiazide may increase the nephrotoxic activities of Sodium phosphate. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Ibopamine Ibopamine may increase the nephrotoxic activities of Sodium phosphate. Experimental Ibuprofen Sodium phosphate may increase the nephrotoxic activities of Ibuprofen. Approved Ibuproxam Sodium phosphate may increase the nephrotoxic activities of Ibuproxam. Withdrawn Icatibant Sodium phosphate may increase the nephrotoxic activities of Icatibant. Approved, Investigational Imidapril Imidapril may increase the nephrotoxic activities of Sodium phosphate. Investigational Imidazole salicylate Sodium phosphate may increase the nephrotoxic activities of Imidazole salicylate. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Sodium phosphate. Approved Indapamide Indapamide may increase the nephrotoxic activities of Sodium phosphate. Approved Indobufen Sodium phosphate may increase the nephrotoxic activities of Indobufen. Investigational Indomethacin Sodium phosphate may increase the nephrotoxic activities of Indomethacin. Approved, Investigational Indoprofen Sodium phosphate may increase the nephrotoxic activities of Indoprofen. Withdrawn Iprindole The risk or severity of adverse effects can be increased when Iprindole is combined with Sodium phosphate. Experimental Irbesartan Irbesartan may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Iron Iron can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Iron Dextran Iron Dextran can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Iron saccharate Iron saccharate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Isosorbide Isosorbide may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Isoxicam Sodium phosphate may increase the nephrotoxic activities of Isoxicam. Withdrawn Kebuzone Sodium phosphate may increase the nephrotoxic activities of Kebuzone. Experimental Ketoprofen Sodium phosphate may increase the nephrotoxic activities of Ketoprofen. Approved, Vet Approved Ketorolac Sodium phosphate may increase the nephrotoxic activities of Ketorolac. Approved Leflunomide Sodium phosphate may increase the nephrotoxic activities of Leflunomide. Approved, Investigational Lisinopril Lisinopril may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Lisofylline Sodium phosphate may increase the nephrotoxic activities of Lisofylline. Investigational Lofepramine The risk or severity of adverse effects can be increased when Lofepramine is combined with Sodium phosphate. Experimental Lonazolac Sodium phosphate may increase the nephrotoxic activities of Lonazolac. Experimental Lornoxicam Sodium phosphate may increase the nephrotoxic activities of Lornoxicam. Approved, Investigational Losartan Losartan may increase the nephrotoxic activities of Sodium phosphate. Approved Loxoprofen Sodium phosphate may increase the nephrotoxic activities of Loxoprofen. Approved, Investigational Lumiracoxib Sodium phosphate may increase the nephrotoxic activities of Lumiracoxib. Approved, Investigational Magaldrate Magaldrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium salicylate Sodium phosphate may increase the nephrotoxic activities of Magnesium salicylate. Approved Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium sulfate The serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Mannitol Mannitol may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Masoprocol Sodium phosphate may increase the nephrotoxic activities of Masoprocol. Approved, Investigational Mebutizide Mebutizide may increase the nephrotoxic activities of Sodium phosphate. Experimental Meclofenamic acid Sodium phosphate may increase the nephrotoxic activities of Meclofenamic acid. Approved, Vet Approved Mefenamic acid Sodium phosphate may increase the nephrotoxic activities of Mefenamic acid. Approved Mefruside Mefruside may increase the nephrotoxic activities of Sodium phosphate. Experimental Melitracen The risk or severity of adverse effects can be increased when Melitracen is combined with Sodium phosphate. Experimental, Investigational Meloxicam Sodium phosphate may increase the nephrotoxic activities of Meloxicam. Approved, Vet Approved Mersalyl Mersalyl may increase the nephrotoxic activities of Sodium phosphate. Approved Mesalazine Sodium phosphate may increase the nephrotoxic activities of Mesalazine. Approved Metamizole Sodium phosphate may increase the nephrotoxic activities of Metamizole. Approved, Investigational, Withdrawn Methazolamide Methazolamide may increase the nephrotoxic activities of Sodium phosphate. Approved Methyclothiazide Methyclothiazide may increase the nephrotoxic activities of Sodium phosphate. Approved Meticrane Meticrane may increase the nephrotoxic activities of Sodium phosphate. Experimental Metolazone Metolazone may increase the nephrotoxic activities of Sodium phosphate. Approved Mizoribine Sodium phosphate may increase the nephrotoxic activities of Mizoribine. Investigational Moexipril Moexipril may increase the nephrotoxic activities of Sodium phosphate. Approved Mofebutazone Sodium phosphate may increase the nephrotoxic activities of Mofebutazone. Experimental Muzolimine Muzolimine may increase the nephrotoxic activities of Sodium phosphate. Experimental Mycophenolate mofetil Sodium phosphate may increase the nephrotoxic activities of Mycophenolate mofetil. Approved, Investigational Mycophenolic acid Sodium phosphate may increase the nephrotoxic activities of Mycophenolic acid. Approved Nabumetone Sodium phosphate may increase the nephrotoxic activities of Nabumetone. Approved Nafamostat Sodium phosphate may increase the nephrotoxic activities of Nafamostat. Approved, Investigational Naftifine Sodium phosphate may increase the nephrotoxic activities of Naftifine. Approved Naproxen Sodium phosphate may increase the nephrotoxic activities of Naproxen. Approved, Vet Approved Nepafenac Sodium phosphate may increase the nephrotoxic activities of Nepafenac. Approved, Investigational Nifenazone Sodium phosphate may increase the nephrotoxic activities of Nifenazone. Experimental Niflumic Acid Sodium phosphate may increase the nephrotoxic activities of Niflumic Acid. Approved Nimesulide Sodium phosphate may increase the nephrotoxic activities of Nimesulide. Approved, Investigational, Withdrawn Nitroaspirin Sodium phosphate may increase the nephrotoxic activities of Nitroaspirin. Investigational Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Sodium phosphate. Approved Olmesartan Olmesartan may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Olopatadine Sodium phosphate may increase the nephrotoxic activities of Olopatadine. Approved Olsalazine Sodium phosphate may increase the nephrotoxic activities of Olsalazine. Approved Omapatrilat Omapatrilat may increase the nephrotoxic activities of Sodium phosphate. Investigational Opipramol The risk or severity of adverse effects can be increased when Opipramol is combined with Sodium phosphate. Investigational Orgotein Sodium phosphate may increase the nephrotoxic activities of Orgotein. Vet Approved Oxaprozin Sodium phosphate may increase the nephrotoxic activities of Oxaprozin. Approved Oxyphenbutazone Sodium phosphate may increase the nephrotoxic activities of Oxyphenbutazone. Approved, Withdrawn Palmidrol Sodium phosphate may increase the nephrotoxic activities of Palmidrol. Experimental, Nutraceutical Parecoxib Sodium phosphate may increase the nephrotoxic activities of Parecoxib. Approved Parthenolide Sodium phosphate may increase the nephrotoxic activities of Parthenolide. Approved, Investigational Perindopril Perindopril may increase the nephrotoxic activities of Sodium phosphate. Approved Phenylbutazone Sodium phosphate may increase the nephrotoxic activities of Phenylbutazone. Approved, Vet Approved Pimecrolimus Sodium phosphate may increase the nephrotoxic activities of Pimecrolimus. Approved, Investigational Piretanide Piretanide may increase the nephrotoxic activities of Sodium phosphate. Approved Pirfenidone Sodium phosphate may increase the nephrotoxic activities of Pirfenidone. Approved, Investigational Piroxicam Sodium phosphate may increase the nephrotoxic activities of Piroxicam. Approved, Investigational Pirprofen Sodium phosphate may increase the nephrotoxic activities of Pirprofen. Experimental Polythiazide Polythiazide may increase the nephrotoxic activities of Sodium phosphate. Approved Potassium Potassium may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Potassium Citrate Potassium Citrate may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational, Vet Approved Pranoprofen Sodium phosphate may increase the nephrotoxic activities of Pranoprofen. Experimental, Investigational Proglumetacin Sodium phosphate may increase the nephrotoxic activities of Proglumetacin. Experimental Propacetamol Sodium phosphate may increase the nephrotoxic activities of Propacetamol. Approved, Investigational Propyphenazone Sodium phosphate may increase the nephrotoxic activities of Propyphenazone. Experimental Proquazone Sodium phosphate may increase the nephrotoxic activities of Proquazone. Experimental Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Sodium phosphate. Approved PTC299 Sodium phosphate may increase the nephrotoxic activities of PTC299. Investigational Quinapril Quinapril may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Quinethazone Quinethazone may increase the nephrotoxic activities of Sodium phosphate. Approved Ramipril Ramipril may increase the nephrotoxic activities of Sodium phosphate. Approved Rescinnamine Rescinnamine may increase the nephrotoxic activities of Sodium phosphate. Approved Resveratrol Sodium phosphate may increase the nephrotoxic activities of Resveratrol. Approved, Experimental, Investigational Rofecoxib Sodium phosphate may increase the nephrotoxic activities of Rofecoxib. Approved, Investigational, Withdrawn Rolofylline Rolofylline may increase the nephrotoxic activities of Sodium phosphate. Investigational Sacubitril Sacubitril may increase the nephrotoxic activities of Sodium phosphate. Approved Salicylamide Sodium phosphate may increase the nephrotoxic activities of Salicylamide. Approved Salicylic acid Sodium phosphate may increase the nephrotoxic activities of Salicylic acid. Approved, Investigational, Vet Approved Salsalate Sodium phosphate may increase the nephrotoxic activities of Salsalate. Approved Saprisartan Saprisartan may increase the nephrotoxic activities of Sodium phosphate. Experimental Saralasin Saralasin may increase the nephrotoxic activities of Sodium phosphate. Investigational Semapimod Sodium phosphate may increase the nephrotoxic activities of Semapimod. Investigational Seratrodast Sodium phosphate may increase the nephrotoxic activities of Seratrodast. Approved Serrapeptase Sodium phosphate may increase the nephrotoxic activities of Serrapeptase. Investigational Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Spiradoline Spiradoline may increase the nephrotoxic activities of Sodium phosphate. Investigational Spirapril Spirapril may increase the nephrotoxic activities of Sodium phosphate. Approved Spironolactone Spironolactone may increase the nephrotoxic activities of Sodium phosphate. Approved SRT501 Sodium phosphate may increase the nephrotoxic activities of SRT501. Investigational Sucralfate Sucralfate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sulfasalazine Sodium phosphate may increase the nephrotoxic activities of Sulfasalazine. Approved Sulindac Sodium phosphate may increase the nephrotoxic activities of Sulindac. Approved, Investigational Suprofen Sodium phosphate may increase the nephrotoxic activities of Suprofen. Approved, Withdrawn Suxibuzone Sodium phosphate may increase the nephrotoxic activities of Suxibuzone. Experimental Tarenflurbil Sodium phosphate may increase the nephrotoxic activities of Tarenflurbil. Investigational Tasosartan Tasosartan may increase the nephrotoxic activities of Sodium phosphate. Approved Telmisartan Telmisartan may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Temocapril Temocapril may increase the nephrotoxic activities of Sodium phosphate. Experimental, Investigational Tenidap Sodium phosphate may increase the nephrotoxic activities of Tenidap. Experimental Tenoxicam Sodium phosphate may increase the nephrotoxic activities of Tenoxicam. Approved Tepoxalin Sodium phosphate may increase the nephrotoxic activities of Tepoxalin. Vet Approved Teriflunomide Sodium phosphate may increase the nephrotoxic activities of Teriflunomide. Approved Theobromine Theobromine may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Tianeptine The risk or severity of adverse effects can be increased when Tianeptine is combined with Sodium phosphate. Approved, Investigational Tiaprofenic acid Sodium phosphate may increase the nephrotoxic activities of Tiaprofenic acid. Approved Ticrynafen Ticrynafen may increase the nephrotoxic activities of Sodium phosphate. Withdrawn Tinoridine Sodium phosphate may increase the nephrotoxic activities of Tinoridine. Investigational Tolfenamic Acid Sodium phosphate may increase the nephrotoxic activities of Tolfenamic Acid. Approved, Investigational Tolmetin Sodium phosphate may increase the nephrotoxic activities of Tolmetin. Approved Tolvaptan Tolvaptan may increase the nephrotoxic activities of Sodium phosphate. Approved Torasemide Torasemide may increase the nephrotoxic activities of Sodium phosphate. Approved Trandolapril Trandolapril may increase the nephrotoxic activities of Sodium phosphate. Approved Tranilast Sodium phosphate may increase the nephrotoxic activities of Tranilast. Approved, Investigational Triamterene Triamterene may increase the nephrotoxic activities of Sodium phosphate. Approved Tribenoside Sodium phosphate may increase the nephrotoxic activities of Tribenoside. Experimental Trichlormethiazide Trichlormethiazide may increase the nephrotoxic activities of Sodium phosphate. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Sodium phosphate. Approved Triptolide Sodium phosphate may increase the nephrotoxic activities of Triptolide. Investigational Tromethamine Tromethamine can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ularitide Ularitide may increase the nephrotoxic activities of Sodium phosphate. Investigational Valdecoxib Sodium phosphate may increase the nephrotoxic activities of Valdecoxib. Approved, Investigational, Withdrawn Valsartan Valsartan may increase the nephrotoxic activities of Sodium phosphate. Approved, Investigational Xipamide Xipamide may increase the nephrotoxic activities of Sodium phosphate. Experimental Zaltoprofen Sodium phosphate may increase the nephrotoxic activities of Zaltoprofen. Approved, Investigational Zileuton Sodium phosphate may increase the nephrotoxic activities of Zileuton. Approved, Investigational, Withdrawn Zofenopril Zofenopril may increase the nephrotoxic activities of Sodium phosphate. Experimental Zomepirac Sodium phosphate may increase the nephrotoxic activities of Zomepirac. Withdrawn - Food Interactions
- Not Available
References
- General References
- Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
- Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
- Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
- Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- FDA Guide: Sodium Phosphate Tablet [Link]
- ChemIDPlus: Sodium Phosphate [Link]
- External Links
- PubChem Compound
- 23672064
- PubChem Substance
- 347827853
- ChemSpider
- 22626
- ChEBI
- 37585
- ChEMBL
- CHEMBL1368
- Wikipedia
- Sodium_phosphates
- ATC Codes
- A06AD17 — Sodium phosphate
- A06AD — Osmotically acting laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- B05XA — Electrolyte solutions
- B05X — I.V. SOLUTION ADDITIVES
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- FDA label
- Download (359 KB)
- MSDS
- Download (84.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Prevention Plasmodium Infections 1 2 Completed Basic Science Colonoscopy 1 2 Completed Screening Healthy Volunteers 1 3 Active Not Recruiting Treatment X-Linked Hypophosphatemia 1 3 Completed Not Available Colonoscopy 1 3 Completed Diagnostic Bowel Preparation, Efficacy, Tolerability, Safety 1 3 Completed Treatment Cataracts 2 3 Completed Treatment Colon Cleansing 1 3 Completed Treatment Colonoscopy 2 4 Completed Not Available Eye Dryness 1 4 Completed Diagnostic Colonoscopy 1 4 Completed Other Sickle Cell Disorders 1 4 Completed Treatment Colon Cleansing 1 4 Completed Treatment Colonoscopy 2 4 Completed Treatment Colorectal Cleansing Prior Operation 1 4 Completed Treatment Psoriasis / Sleep Apnea, Obstructive 1 4 Not Yet Recruiting Basic Science Heart Defects,Congenital 1 4 Recruiting Treatment Transient Hypoparathyroidism 1 Not Available Completed Other Laparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy 1 Not Available Completed Screening Colorectal Cancers 1 Not Available Recruiting Not Available Healthy Adults 1 Not Available Recruiting Other Chronic Kidney Disease (CKD) 1 Not Available Terminated Treatment Colonoscopy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Solution Unknown Tablet Oral Powder, for solution Intraocular Injection, solution Intravenous Kit Kit; solution Intraocular Liquid Intravenous Solution Intravenous Paste Dental Injection Intrathecal Kit Intravenous Liquid Rectal Solution Extracorporeal Liquid Intravesical Kit Liquid Buccal Spray Buccal Kit Intravenous Kit; solution Intraocular; Irrigation Liquid Topical Tablet, effervescent Oral Rinse Dental Solution Oral Enema Rectal Liquid Oral Solution Respiratory (inhalation) Powder Oral Irrigant Irrigation Liquid Irrigation Capsule Oral Tablet, coated Oral - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7687075 No 2008-06-22 2028-06-22 US US7084130 No 2001-11-29 2021-11-29 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes at 75 MSDS water solubility 121 g/L MSDS - Predicted Properties
Property Value Source logP -1 ChemAxon pKa (Strongest Acidic) 1.8 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 80.59 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 13.53 m3·mol-1 ChemAxon Polarizability 5.53 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Taxonomy
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic sodium salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- sodium phosphate (CHEBI:37585)
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- SLC20A1
- Uniprot ID
- Q8WUM9
- Uniprot Name
- Sodium-dependent phosphate transporter 1
- Molecular Weight
- 73699.01 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Homo sapiens
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Virus receptor activity
- Specific Function
- Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
- Gene Name
- SLC20A2
- Uniprot ID
- Q08357
- Uniprot Name
- Sodium-dependent phosphate transporter 2
- Molecular Weight
- 70391.755 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Homo sapiens
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
- Gene Name
- SLC34A1
- Uniprot ID
- Q06495
- Uniprot Name
- Sodium-dependent phosphate transport protein 2A
- Molecular Weight
- 68936.53 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Homo sapiens
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
- Gene Name
- SLC34A2
- Uniprot ID
- O95436
- Uniprot Name
- Sodium-dependent phosphate transport protein 2B
- Molecular Weight
- 75758.535 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
- Kind
- Protein
- Organism
- Homo sapiens
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
- Gene Name
- SLC34A3
- Uniprot ID
- Q8N130
- Uniprot Name
- Sodium-dependent phosphate transport protein 2C
- Molecular Weight
- 63548.94 Da
References
- Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]
Drug created on November 30, 2015 12:10 / Updated on June 19, 2018 06:44